Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,944,818
  • Shares Outstanding, K 28,558
  • Annual Sales, $ 50,700 K
  • Annual Income, $ 10,930 K
  • 60-Month Beta 0.82
  • Price/Sales 97.46
  • Price/Cash Flow N/A
  • Price/Book 5.89
Trade KRYS with:

Options Overview Details

View History
  • Implied Volatility 60.54% ( -0.50%)
  • Historical Volatility 35.73%
  • IV Percentile 66%
  • IV Rank 47.65%
  • IV High 89.43% on 02/16/24
  • IV Low 34.23% on 05/21/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 48
  • Volume Avg (30-Day) 144
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 10,144
  • Open Int (30-Day) 9,238

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.85
  • Number of Estimates 3
  • High Estimate 1.02
  • Low Estimate 0.63
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +226.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
169.00 +5.37%
on 10/10/24
203.29 -12.40%
on 09/16/24
-20.72 (-10.42%)
since 09/11/24
3-Month
164.81 +8.05%
on 08/05/24
219.34 -18.82%
on 07/26/24
-20.33 (-10.25%)
since 07/11/24
52-Week
93.95 +89.54%
on 11/10/23
219.34 -18.82%
on 07/26/24
+65.07 (+57.58%)
since 10/11/23

Most Recent Stories

More News
Pacira's Exparel Receives Permanent New Product-Specific J-Code

Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine...

KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)
PCRX : 16.25 (+4.77%)
Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name Miplyffa.The...

ZVRA : 8.06 (+1.77%)
KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)
RARE's Wilson Disease Candidate Betters Standard Therapy in Study

Ultragenyx Pharmaceutical RARE reported positive updates from the Stage 1 cohorts of its phase I/II/III Cyprus2+ study evaluating UX701, an investigational AAV9 gene therapy, to treat Wilson disease. Stage...

KRYS : 178.10 (+2.86%)
RARE : 54.02 (+0.28%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare...

KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
IONS : 38.57 (+1.63%)
ANIP : 57.16 (+3.74%)
Here's Why Investors Should Consider Buying Corcept Stock Now

Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past...

CORT : 45.26 (+0.02%)
KRYS : 178.10 (+2.86%)
ANIP : 57.16 (+3.74%)
BVS : 12.19 (+8.36%)
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission (SEC) over allegedly misleading statements about the results of its 2020 mid-stage...

KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)
SAVA : 25.74 (+3.54%)
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

Shares of Biomea Fusion BMEA gained 9.1% on Thursday after the FDA lifted the clinical hold it had earlier placed on the company’s ongoing early to mid-stage studies evaluating its lead candidate, BMF-219,...

KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
BMEA : 10.53 (-2.05%)
ANIP : 57.16 (+3.74%)
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for...

CLDX : 30.68 (+3.37%)
KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III REGENCY study...

KRYS : 178.10 (+2.86%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)
RHHBY : 39.1100 (+0.62%)
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study

Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage study evaluating its investigational candidate, WVE-N531, to treat boys with...

KRYS : 178.10 (+2.86%)
WVE : 8.50 (+2.91%)
FULC : 3.46 (+5.81%)
ANIP : 57.16 (+3.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 178.83
2nd Resistance Point 176.04
1st Resistance Point 174.59
Last Price 178.10
1st Support Level 170.35
2nd Support Level 167.56
3rd Support Level 166.11

See More

52-Week High 219.34
Last Price 178.10
Fibonacci 61.8% 171.44
Fibonacci 50% 156.64
Fibonacci 38.2% 141.85
52-Week Low 93.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar